含长效β2受体激动剂药物处方的季节性变化。

Seasonal changes in prescribing of long-acting beta-2-agonists-containing drugs.

作者信息

Rottenkolber M, Voogd E, van Dijk L, Primatesta P, Becker C, de Groot M C H, Plana E, Alvarez Y, Durand J, Slattery J, Afonso A, Requena G, Huerta C, Alvarez A, de Abajo F, Tauscher M, Hasford J, Fischer R, Reynolds R, Schmiedl S

机构信息

Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet Muenchen, Marchioninistr. 15, D-81377 Munich, Germany.

Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Division Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Universiteitsweg 99, NL-3584 CA Utrecht, The Netherlands; Netherlands Institute for Health Services Research, PO Box 1568, 3500 Utrecht, The Netherlands.

出版信息

Respir Med. 2015 Jul;109(7):828-37. doi: 10.1016/j.rmed.2015.01.010. Epub 2015 Jan 31.

DOI:10.1016/j.rmed.2015.01.010

PMID:25976384

Abstract

BACKGROUND

For patients with asthma, COPD, or asthma-COPD overlap syndrome (ACOS), inter-country comparisons of seasonal changes in drug prescriptions are scarce or missing. Hence, we aimed to compare seasonal changes in prescription rates of long-acting beta-2-agonist (LABA) in four European countries.

METHODS

A common study protocol was applied to six health care databases (Germany, Spain, the Netherlands (2), and the UK (2)) to calculate age- and sex-standardized point prevalence rates (PPRs) of LABA-containing prescriptions by the 1st of March, June, September, and December of each year during the study period 2002-2009. Seasonal variation of PPRs was quantified using seasonal indexes (SIs; based on the ratio-to-moving-average-method) and SIs averaged over the study period (aSI) stratified by sex, age, and indication (asthma, COPD, or ACOS).

RESULTS

There was a moderate seasonal change in LABA-containing prescriptions which was more pronounced in asthma or COPD patients compared to ACOS patients. For asthma and ACOS patients, highest seasonal variation was found for patients living in Spain (aSI: 87.3-110.7, aSI: 93.2-103.1) whereas for COPD highest seasonal variation was revealed for the NPCRD database (the Netherlands) (aSI: 92.2-105.6). Regarding age and sex, highest seasonal variation was found in Spanish boys under 10 years of age having a diagnosis of asthma.

CONCLUSIONS

By applying a common analysis in six databases, we could observe moderate overall seasonal changes in LABA-containing prescription rates in patients with asthma, COPD, or ACOS.

摘要

背景

对于哮喘、慢性阻塞性肺疾病（COPD）或哮喘-COPD重叠综合征（ACOS）患者，不同国家间药物处方季节性变化的比较较少或缺乏。因此，我们旨在比较四个欧洲国家长效β2受体激动剂（LABA）处方率的季节性变化。

方法

采用通用研究方案对六个医疗保健数据库（德国、西班牙、荷兰（两个）和英国（两个））进行分析，以计算2002年至2009年研究期间每年3月1日、6月1日、9月1日和12月含LABA处方的年龄和性别标准化点患病率（PPR）。使用季节性指数（SI；基于移动平均比率法）和研究期间的平均SI（aSI）对PPR的季节性变化进行量化，按性别、年龄和适应症（哮喘、COPD或ACOS）分层。

结果

含LABA的处方有中度季节性变化，与ACOS患者相比，哮喘或COPD患者的变化更明显。对于哮喘和ACOS患者，居住在西班牙的患者季节性变化最大（aSI：87.3 - 110.7，aSI：93.2 - 103.1），而对于COPD患者，NPCRD数据库（荷兰）的季节性变化最大（aSI：92.2 - 105.6）。在年龄和性别方面，诊断为哮喘的10岁以下西班牙男孩季节性变化最大。